Glass Jacobson Investment Advisors llc Makes New Investment in NuCana plc (NASDAQ:NCNA)

Glass Jacobson Investment Advisors llc bought a new position in NuCana plc (NASDAQ:NCNA) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 15,000 shares of the company’s stock, valued at approximately $38,000. Glass Jacobson Investment Advisors llc owned about 0.57% of NuCana at the end of the most recent quarter.

Separately, Baillie Gifford & Co. acquired a new stake in shares of NuCana in the second quarter valued at approximately $378,000. 44.00% of the stock is currently owned by hedge funds and other institutional investors.

NuCana Trading Down 5.2 %

Shares of NASDAQ NCNA opened at $3.26 on Friday. The firm has a market capitalization of $8.62 million, a PE ratio of -0.28 and a beta of 1.01. The firm’s 50-day moving average is $4.19 and its 200-day moving average is $4.53. NuCana plc has a 1 year low of $2.34 and a 1 year high of $20.25.

NuCana (NASDAQ:NCNA) last announced its quarterly earnings data on Thursday, August 15th. The company reported ($3.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.55) by ($0.24). As a group, equities research analysts anticipate that NuCana plc will post -13.27 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on NCNA shares. Oppenheimer reduced their price objective on NuCana from $150.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, September 3rd. William Blair lowered NuCana from an “outperform” rating to a “market perform” rating in a research note on Friday, August 30th.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.